Investigational drug · Phase 2
TYK-00540
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for mCRPC, HR-positive, HER2-negative Advanced Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TYK-00540"
First trial start
2024
Jan 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TYK-00540", any sponsor or status.
Conditions studied
As listed on its trial records.
- mCRPC
- HR-positive, HER2-negative Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TYK-00540" as an intervention, largest first.
TYK Medicines, IncIndustry
NCT06950086 · 180 participants (planned) · Start Jan 2, 2024 · Primary completion Sep 2026
Drug: TYK-00540 · For: HR-positive, HER2-negative Advanced Breast Cancer
Sites: Shanghai, China · 2 sites in all
TYK Medicines, IncIndustry
NCT06246071 · 156 participants (planned) · Start Jan 2, 2024 · Primary completion Dec 5, 2026
Drug: TYK-00540 · For: Locally Advanced or Metastatic Solid Tumors
Sites: Hefei, China
- Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)Not yet recruiting
TYK Medicines, IncIndustry
NCT07104643 · 48 participants (planned) · Start Aug 2025 · Primary completion Nov 2026
Drug: TYK-00540; Enzalutamide · For: mCRPC
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for mCRPC
- HC-1119Phase 31 trial
Hinova Pharmaceuticals Inc. · MCRPC
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- ZEN003694ZEN-3694Phase 22 trials
Zenith Epigenetics · mCRPC, Metastatic Castration-Resistant Prostate Cancer
- Ga-68-NGULPhase 21 trial
Cellbion Co., Ltd. · Prostate Cancer, mCRPC
- Lu-177-DGULPhase 21 trial
Cellbion Co., Ltd. · Prostate Cancer, mCRPC
- REGN21353Phase 21 trial
Regeneron · Metastatic Castration-Resistant Prostate Cancer, mCRPC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.